TNFSF11 and Duchenne muscular dystrophy: Four boys with DMD, three on deflazacort (Def; black, red, and yellow dots) and one on prednisolone (Pred, blue dots), were treated for approximately two years with either denosumab, a human monoclonal anti-RANKL (1 mg/kg/6 months, n = 2) or zoledronic acid (Zol), a bisphosphonate (0.025 mg/kg/6 months, n = 2) (Figure 6A) to minimize glucocorticoid (GC)-related bone loss.